Table 1.
E2F1-upregulated target gene signature
| No. | Gene | No. | Gene | No. | Gene | No. | Gene | No. | Gene |
|---|---|---|---|---|---|---|---|---|---|
| 1. | BMP2 | 17. | PCK1 | 33 | RORA | 49. | HPGD | 65. | INHBB |
| 2. | LRIG1 | 18. | BRF1 | 34. | CDKN2C | 50. | ZBTB1 | 66. | H2AFB1 |
| 3. | EIF4A1 | 19. | MAP3K5 | 35. | KIAA0495 | 51. | CCNE2 | 67. | FOXF2 |
| 4. | FOXD1 | 20. | NPTX2 | 36. | HOXD8 | 52. | ARR3 | 68. | MYB |
| 5. | RB1 | 21. | PEG10 | 37. | GATA2 | 53. | GZMB | 69. | NR2F1 |
| 6. | FST | 22. | KLF10 | 38. | PTK7 | 54. | AMY2B | 70. | CDKN1A |
| 7. | FOXA1 | 23. | GNRHR | 39. | CYP26A1 | 55. | ATP8A1 | 71. | BAI2 |
| 8. | VEGFC | 24. | FOXO1 | 40. | TCF7 | 56. | WIF1 | 72. | F3 |
| 9. | PTHLH | 25. | FGFR1 | 41. | PLAG1 | 57. | IRX5 | 73. | CDKN1B |
| 10. | DUSP2 | 26. | AKAP5 | 42. | DLX2 | 58. | C8G | 74. | SKP2 |
| 11. | NHLH2 | 27. | EFNB2 | 43. | GNAO1 | 59. | MPP6 | 75. | STX11 |
| 12. | ABCC4 | 28. | LOC652637 | 44. | KITLG | 60. | KIAA1107 | 76. | RBM38 |
| 13. | RFPL3S | 29. | TERF2 | 45. | CSPG5 | 61. | PKLR | 77. | FGF9 |
| 14. | ZIC3 | 30. | PLCL2 | 46. | LHX2 | 62. | CCNE1 | ||
| 15. | IRF1 | 31. | ESR2 | 47. | ABCA2 | 63. | SYNGR3 | ||
| 16. | FGFR3 | 32. | CHST1 | 48. | BCL2L11 | 64. | MAN1C1 |
All genes displaying a ≥5-fold higher expression in E2F1 overexpressing melanoma SK-MEL-2 cells compared to control SK-MEL-2 cells (data set NCBI GEO accession number GSE1562). Genes are displayed in order of most positively enriched (genes 1–35) to the most negatively enriched (genes 37–77) in the γ-Tubulin-shRNA-transfected cells. HOXD8 (gene 36) displayed no enrichment.